| 000 | 00870 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250518051540.0 | ||
| 264 | 0 | _c20191010 | |
| 008 | 201910s 0 0 eng d | ||
| 022 | _a1474-547X | ||
| 024 | 7 |
_a10.1016/S0140-6736(19)31663-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBradley, John | |
| 245 | 0 | 0 |
_aAnalysis of the RIMDAMAL trial. _h[electronic resource] |
| 260 |
_bLancet (London, England) _c09 2019 |
||
| 300 |
_a1005-1006 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIvermectin |
| 650 | 0 | 4 | _aMalaria |
| 650 | 0 | 4 | _aMass Drug Administration |
| 700 | 1 | _aMoulton, Lawrence H | |
| 700 | 1 | _aHayes, Richard | |
| 773 | 0 |
_tLancet (London, England) _gvol. 394 _gno. 10203 _gp. 1005-1006 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(19)31663-0 _zAvailable from publisher's website |
| 999 |
_c29919409 _d29919409 |
||